Stony Brook Experts

an online search tool for members of the media to identify experts at Stony Brook

Search experts:

or

Browse experts:

View all departments View all topics View all experts Close
Hal A Skopicki Cardiologist, Director, Heart Failure and Cardiomyopathy Center, Co-Director, Mechanical Ventricular Assist Device (VAD) Program Stony Brook Heart Institute Medicine School of Medicine

Contact Information

080 Health Sciences Center

Stony Brook, 11794

631/444-1069

Biography

Hal Skopicki specializes in advanced/complex cardiac disease involving the heart muscle, valves, arteries, or overall heart function. His expertise includes the diagnosis and treatment of all forms of heart failure, and extends to cutting-edge technologies as a principal researcher for investigations involving stem cells, genetic analysis, and state-of-the-art medical therapy. He regularly treats patients with severe heart failure and is an expert in assessing their options.  

Education

  • Medical School, Rosalind Franklin Medical School
  • Residency, Yale-New Haven Hospital, Medicine
  • Fellowship, Massachusetts General Hospital, Internal Medicine-Cardiology

Research Grants

Award Start End Sponsor Type Amount Status
Immune Activation and Myocardial Recovery in Peripartum Cardiomyopathy 2009-09-30T00:00:00 2013-12-31T00:00:00 University of Pittsburgh Nonfederal 1400 Closed
A Multi-Center, Placebo-Controlled, Study to Evaluate the Safety of GSK716155 and its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients with NYHA Class II/III Congestive Heart Failure 2011-05-10T00:00:00 2013-06-15T00:00:00 GlaxoSmithKline Nonfederal 52263.4 Closed
The Balance Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation 2008-04-23T00:00:00 2011-12-02T00:00:00 Cardiokine Biopharma, LLC Nonfederal 13530 Closed
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects with Diastolic Heart Failure 2008-10-24T00:00:00 2010-10-08T00:00:00 Synvista Therapeutics Incorporated Nonfederal 3300 Closed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effect of Intravenous BG9928 on Body Weight in Subjects with Acute Decompensated Heart Failure and Renal Insufficiency 2009-04-30T00:00:00 2011-02-11T00:00:00 Biogen Idec Nonfederal 5000 Closed
SITE 1055: Double-Blinded, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure 2008-05-22T00:00:00 2012-01-13T00:00:00 Scios Incorporated Nonfederal 140500 Closed
Pre-Determine: Biologic Markers and MRI SCD Cohort Study 2012-07-01T00:00:00 2015-01-06T00:00:00 Brigham and Womens Hospital Nonfederal 300 Closed
Management of Patients with Acutely Decompensated Heart Failure 2012-05-14T00:00:00 2014-05-02T00:00:00 OptumHealth Care Solutions Incorporated Nonfederal 37800 Closed
Cyclin Dependent Kinase G in Cardiac Development 2006-09-01T00:00:00 2009-03-31T00:00:00 National Heart Lung and Blood Institute Federal 761150.48 Closed
Solvay Pharma: A Double-Blind, Placebo-Controlled, Randomized, Multi-Center, Dose-Finding Study of SLV320, a Selective A1 Adenosine Receptor Antagonist, to Evaluate the Effect on Renal Function and Safety in Subjects Hospitalized..... 2009-09-10T00:00:00 2010-07-08T00:00:00 Quintiles Incorporated Nonfederal 3000 Closed
A Phase II/III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects with Acute Heart Failure 2010-08-30T00:00:00 2013-07-30T00:00:00 Corthera Incorporated Nonfederal 5500 Closed
MIRACLE EF Study: Cardiac Resynchronization Therapy in Heart Failure 2013-01-23T00:00:00 2015-04-28T00:00:00 Medtronic Incorporated Nonfederal 12266 Closed
Cardiorentis: Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ularitide (Urodilatin) Intravenous Infusion in Patients Suffering from Acute Decompensated Heart Failure 2013-03-18T00:00:00 2015-05-20T00:00:00 Quintiles Incorporated Nonfederal 5875 Closed
Phosphodiesterase Type 5 Inhibition with Tadalafil Changes Outcomes in Heart Failure (PITCH-HF) 2013-12-02T00:00:00 2015-05-05T00:00:00 New England Research Institute Nonfederal 2500 Closed
INTERVENE-HF Integrated Diagnostics Driven Diuretic & Chronic Medication Management for Heart Failure 2016-08-02T00:00:00 2017-08-02T00:00:00 Medtronic Incorporated Nonfederal 1428 Approved
Entresto (LCZ696) In Hospitalized Advanced Heart Failure (LIFE Study) 2017-02-28T00:00:00 2018-10-31T00:00:00 Duke University Nonfederal 1 Approved
Multicenter, Randomized, Double-Blind, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Both Aliskiren Monotherapy and Aliskiren/Enalapril Combination Therapy Compared to Enalapril Monotherapy, on Morbidity... 2009-11-10T00:00:00 2017-05-31T00:00:00 Novartis Pharmaceuticals Corporation Nonfederal 56869.41 Closed
RiboCor: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate D-Ribose for the Treatment of Congestive Heart Failure 2013-09-24T00:00:00 2017-03-31T00:00:00 Integrium LLC Nonfederal 6448.58 Closed
A Phase IIa, Single-Blind, Placebo-Controlled, Crossover, Multi-Center, Randomized Study to Assess The Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Ischemia-Tolerant Allogeneic Mesenchymal Bone Marrow.... 2015-02-27T00:00:00 2017-12-05T00:00:00 CardioCell Limited Liability Company Nonfederal 236993.25 Approved
ATHENA: Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy-HF 2015-02-06T00:00:00 2017-04-30T00:00:00 Duke University Nonfederal 27185 Closed
INcrease Of VAgal TonE in chronic Heart Failure (INOVATE-HF) 2013-09-09T00:00:00 2017-05-01T00:00:00 BioControl Medical Incorporated Nonfederal 31071.8 Approved
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients 2014-01-28T00:00:00 2018-11-26T00:00:00 Novartis Pharmaceuticals Corporation Nonfederal 66726.61 Approved
International Registry to Assess mEdical Practice with IOngitudinal Observation for Treatment of Heart Failure (Report-HF) 2015-10-20T00:00:00 2018-05-24T00:00:00 Novartis Pharmaceuticals Corporation Nonfederal 55603.5 Approved
Observational Registry of Treatment Patterns in U.S. Heart Failure Patients with Reduced Ejection Fraction 2016-10-25T00:00:00 2018-09-27T00:00:00 Novartis Pharmaceuticals Corporation Nonfederal 22440 Approved
Phase II Trial to Study Efficacy Safety Pharmacokinetic & Pharmacodynamic Effects of the Oral Partial Adenosine A1 Receptor Agonist Neladenoson Bialanate over 20 weeks in Patients with Chronic Heart Failure with Reduced Ejection Fraction 2017-04-25T00:00:00 2018-04-11T00:00:00 Bayer Healthcare Pharmaceuticals Incorporated Nonfederal 20065.2 Approved
A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced... 2017-05-16T00:00:00 2018-02-21T00:00:00 Merck Sharp and Dohme Corporation Nonfederal 10937 Approved
Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients without Antiplatelet Therapy 2017-06-07T00:00:00 2018-03-08T00:00:00 St. Jude Medical Incorporated Nonfederal 15180 Approved
Quintiles: A Phase III Randomized, Double-Blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients with Chronic Heart Failure with Preserved Ejection Fraction (HFpEF) 2017-11-02T00:00:00 2018-09-19T00:00:00 Boehringer Ingelheim Pharmaceutical Nonfederal 7875 Approved
Quintiles: A Phase III Randomized, Double-Blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10mg Compared to Placebo in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) 2017-12-28T00:00:00 2018-10-20T00:00:00 Boehringer Ingelheim Pharmaceutical Nonfederal 1 Approved

Publications

  1. Author Article Journal of Cardiac Failure Significant Tricuspid Regurgitation Predicts Mortality in Patients Hospitalized With Acutely Decompensated Heart Failure 2010 16 8
  2. Author Article Journal of Cardiac Failure Echocardiographic Parameters in Women vs Men Admitted With Acutely Decompensated Heart Failure: Are We Treating the Same Disease? 2010 16 8

Video